2023
Individual myasthenia gravis autoantibody clones can efficiently mediate multiple mechanisms of pathology
Pham M, Masi G, Patzina R, Obaid A, Oxendine S, Oh S, Payne A, Nowak R, O’Connor K. Individual myasthenia gravis autoantibody clones can efficiently mediate multiple mechanisms of pathology. Acta Neuropathologica 2023, 146: 319-336. PMID: 37344701, PMCID: PMC11380498, DOI: 10.1007/s00401-023-02603-y.Peer-Reviewed Original ResearchConceptsMyasthenia gravisAntigenic modulationPathogenic mechanismsAutoimmune myasthenia gravisCurrent therapeutic approachesΑ-bungarotoxin bindingNicotinic acetylcholine receptorsReceptor blockadeSerum autoantibodiesAutoreactive clonesMonoclonal levelTherapeutic approachesMonoclonal autoantibodiesAcetylcholine receptorsComplement activationAutoantibodiesAChR subunitsJurkat cell lineDistinct molecular mechanismsPathogenic profilePathogenic capacityPathologyCell-based assaysMAbsPatientsClinicoserological insights into patients with immune checkpoint inhibitor‐induced myasthenia gravis
Masi G, Pham M, Karatz T, Oh S, Payne A, Nowak R, Howard J, Guptill J, Juel V, O'Connor K. Clinicoserological insights into patients with immune checkpoint inhibitor‐induced myasthenia gravis. Annals Of Clinical And Translational Neurology 2023, 10: 825-831. PMID: 36924454, PMCID: PMC10187728, DOI: 10.1002/acn3.51761.Peer-Reviewed Original ResearchMeSH KeywordsAutoantibodiesComplement ActivationHumansImmune Checkpoint InhibitorsMyasthenia GravisReceptors, Cholinergic
2022
Novel pathophysiological insights in autoimmune myasthenia gravis
Masi G, O’Connor K. Novel pathophysiological insights in autoimmune myasthenia gravis. Current Opinion In Neurology 2022, 35: 586-596. PMID: 35942663, PMCID: PMC9458626, DOI: 10.1097/wco.0000000000001088.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsAutoimmune myasthenia gravisMyasthenia gravisMG patientsClinical responseMuscle-specific tyrosine kinaseSpecific therapeutic strategiesNovel pathophysiological insightsMG pathologyMG subtypesAutoantibody repertoireTreatment optionsCancer immunotherapyPredictive biomarkersSuch therapyImmunological heterogeneityPathophysiological insightsMG phenotypeTherapeutic strategiesClinical observationsTherapeutic outcomesAcetylcholine receptorsDisease subtypesTherapeutic perspectivesSubtypesDevelopment of assaysThe clinical need for clustered AChR cell-based assay testing of seronegative MG
Masi G, Li Y, Karatz T, Pham MC, Oxendine SR, Nowak RJ, Guptill JT, O'Connor KC. The clinical need for clustered AChR cell-based assay testing of seronegative MG. Journal Of Neuroimmunology 2022, 367: 577850. PMID: 35366559, PMCID: PMC9106915, DOI: 10.1016/j.jneuroim.2022.577850.Peer-Reviewed Original ResearchConceptsSNMG patientsMyasthenia gravisAChR-specific B cellsClinical needAcetylcholine receptor autoantibodiesSeronegative MG patientsSeronegative myasthenia gravisCell-based assaysAutoantibody positivityTrial eligibilityMG patientsReceptor autoantibodiesPatientsB cellsU.S. CentersNew treatmentsAssaysGravisAutoantibodiesSerostatusAChRPositivity
2021
GABA-cadabra: autoantibodies trick neurotransmitter receptors and induce seizures.
Masi G, O'Connor KC. GABA-cadabra: autoantibodies trick neurotransmitter receptors and induce seizures. Science Immunology 2021, 6: eabn3790. PMID: 34860582, DOI: 10.1126/sciimmunol.abn3790.Peer-Reviewed Original Research